Want to see HK:0314 full AI Analyst Report?
0314 Stock Chart & Stats
HK$2.48
HK$0.09(1.75%)
At close: 4:00 PM EST
HK$2.48
HK$0.09(1.75%)
Day’s Range― - ―
52-Week RangeHK$1.13 - HK$6.10
Previous CloseN/A
Volume1.18M
Average Volume (3M)2.05M
Market Cap
HK$804.47M
Enterprise ValueHK$709.46
Total Cash (Recent Filing)HK$597.85M
Total Debt (Recent Filing)HK$24.70M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding765,767,940
10 Day Avg. Volume1,436,880
30 Day Avg. Volume2,048,921
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.44
Price to Sales (P/S)0.67
P/FCF Ratio10.60K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$1.92B
Bulls Say, Bears Say
Bulls Say
Low Leverage & Positive EquityThe company’s very low debt-to-equity (about 2% in 2025) and positive equity position materially reduce solvency risk and preserve financial optionality. Over 2–6 months this stable capital structure supports operations, limits interest burden, and makes external financing less urgent while losses are being addressed.
Improving Gross Margin And Smaller LossesAn improvement in gross margin alongside materially smaller recent losses points to structural cost control or favorable mix changes. If sustained, higher margins enhance operating leverage and reduce required revenue to reach break-even, improving long-term resilience versus prior high-loss years.
Operating Cash Flow Turned Modestly PositiveThe 2025 inflection to positive operating cash flow indicates the core business is starting to generate cash. This reduces dependency on external funding and, if maintained, can finance working capital or strategic initiatives over the medium term, improving sustainability despite prior cash stress.
Bears Say
Steep Revenue DeclineA roughly 41% revenue drop in 2025 is a structural headwind: loss of scale undermines fixed-cost absorption, pressures margins despite recent improvement, and weakens market position. Sustained revenue contraction would impede progress to profitability and limit reinvestment capacity over coming quarters.
Persistent Operating And Net LossesOngoing operating and net losses across reported periods erode retained capital and constrain strategic flexibility. Continued negative earnings mean reliance on financing or asset sales to fund operations, making durable recovery dependent on reversing revenue trends or delivering sustained margin gains.
Fragile Free Cash Flow HistoryFree cash flow only reached near-breakeven in 2025 after several years of meaningful negative FCF. That fragile cash profile limits the firm’s ability to self-fund growth, increases reliance on external capital in stress scenarios, and raises execution risk for longer-term strategic initiatives.
Sipai Health Technology Co., Ltd. News
0314 FAQ
What was Sipai Health Technology Co., Ltd.’s price range in the past 12 months?
Sipai Health Technology Co., Ltd. lowest stock price was HK$1.13 and its highest was HK$6.10 in the past 12 months.
What is Sipai Health Technology Co., Ltd.’s market cap?
Sipai Health Technology Co., Ltd.’s market cap is HK$804.47M.
When is Sipai Health Technology Co., Ltd.’s upcoming earnings report date?
Sipai Health Technology Co., Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 5 days.
How were Sipai Health Technology Co., Ltd.’s earnings last quarter?
Sipai Health Technology Co., Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.097 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sipai Health Technology Co., Ltd. overvalued?
According to Wall Street analysts Sipai Health Technology Co., Ltd.’s price is currently Overvalued.
Does Sipai Health Technology Co., Ltd. pay dividends?
Sipai Health Technology Co., Ltd. does not currently pay dividends.
What is Sipai Health Technology Co., Ltd.’s EPS estimate?
Sipai Health Technology Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sipai Health Technology Co., Ltd. have?
Sipai Health Technology Co., Ltd. has 765,767,940 shares outstanding.
What happened to Sipai Health Technology Co., Ltd.’s price movement after its last earnings report?
Sipai Health Technology Co., Ltd. reported an EPS of -HK$0.097 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.367%.
Which hedge fund is a major shareholder of Sipai Health Technology Co., Ltd.?
Currently, no hedge funds are holding shares in HK:0314
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sipai Health Technology Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
Sipai Health Technology Co., Ltd.
Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health Insurance Services. The Specialty Pharmacy division manages a network of dedicated pharmacies and is also involved in the distribution of pharmaceutical products to drug manufacturers and other supply chain partners. Through its Physician Research Assistance segment, Sipai Health provides comprehensive site management organization (SMO) support to pharmaceutical firms and clinical research institutions. These services encompass a broad spectrum, including site identification and setup, patient acquisition and oversight, data and document handling, on-site logistical management of drugs and biosamples, and trial conclusion. Additionally, this segment offers specialized image management for clinical studies. The Health Insurance Services division functions as an intermediary, delivering brokerage solutions to various insurance providers. Established in 2014, the company's headquarters are situated in Guangzhou, China.
Technical Analysis
Dingdang Health Technology Group Ltd.
―
EC Healthcare
―
Mediwelcome Healthcare Management & Technology Inc.
―
Beijing Airdoc Technology Co. Ltd. Class H
―
NEUSOFT XIKANG HOLDINGS INC.
―